SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.84 USD
-0.06 (-2.07%)
Updated Sep 6, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for SAB Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 24 | 61 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 2 | 24 | 61 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 40 | 53 | 74 | 0 | 0 |
Income After Depreciation & Amortization | -38 | -29 | -13 | 0 | 0 |
Non-Operating Income | -4 | 11 | -3 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -42 | -19 | -17 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -42 | -19 | -17 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -42 | -19 | -17 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -34 | -26 | -12 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 4 | 3 | 2 | 0 | NA |
Income After Depreciation & Amortization | -38 | -29 | -13 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.52 | 4.35 | 2.73 | NA | NA |
Diluted EPS Before Non-Recurring Items | -7.64 | -6.10 | -6.30 | NA | NA |
Diluted Net EPS (GAAP) | -7.64 | -4.30 | -6.30 | NA | NA |
Fiscal Year end for SAB Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.26 | 0.94 | 0.31 | 1.27 | 0.09 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.26 | 0.94 | 0.31 | 1.27 | 0.09 |
SG&A, R&D, and Dept/Amort Expenses | 10.46 | 12.34 | 19.18 | 6.59 | 6.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.20 | -11.40 | -18.87 | -5.32 | -6.47 |
Non-Operating Income | 2.96 | 6.44 | -3.91 | 0.29 | -0.33 |
Interest Expense | 0.09 | 0.08 | 0.08 | 0.07 | 0.08 |
Pretax Income | -7.34 | -5.03 | -22.86 | -5.10 | -6.88 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.34 | -5.03 | -22.86 | -5.10 | -6.88 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.34 | -5.03 | -22.86 | -5.10 | -6.88 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 9.26 | 9.24 | NA | 5.24 | 5.04 |
Diluted EPS Before Non-Recurring Items | -0.79 | -0.54 | NA | -1.00 | -1.40 |
Diluted Net EPS (GAAP) | -0.79 | -0.54 | -3.74 | -1.00 | -1.40 |